By strengthening our ties to MedTech in Israel, the team at OurCrowd is continuing our commitment to education and innovation.
As a leading investor in medical technology, based in the heart of Israel, famous for its role in medical developments, our investment team and medical advisory board have worked diligently to recognize the potential of Israeli startups. In identifying impressive technologies, like ReWalk Robotics (NASDAQ) and big data analyst Zebra Medical Vision, OurCrowd is focused on bringing MedTech startups the capital and global growth network they need. Once invested, we’re focused on supporting portfolio companies by providing human capital: talent.
As such, the team at OurCrowd is pleased to announce our partnership with Hebrew University, Israel’s leading academic institution, consistently ranked in the world’s top 100 Universities. OurCrowd is sponsoring a new MBA program for biomedical management. The program is the first of its kind in Israel, following academic institutions like Berkley and Johns Hopkins. Its graduates will lead the sector, having been well prepared to tackle its unique challenges from a management perspective.
OurCrowd’s Venture Partner Dr. Morris Laster will lead the way as a course coordinator and lecturer in the MBA Program. He has over 20 years of experience in the development and management of advanced biomedical drugs and technologies. Having founded six public companies both in Israel and abroad, he has most recently invented and developed an implantable artificial kidney system, and built Clil Medical around it. His expertise will help bring the program to success.
OurCrowd is confident the program will provide new top-notch talent for the forward-thinking market. It will be tailored specifically for the Biomedical and MedTech fields. As founder Jon Medved says “The biomedical world has a wealth of its own niche activities, and OurCrowd is pleased to draw people to this academic program.”
Want to learn more about the MBA? Click here.
